OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Syneos Health Consulting, a biopharmaceutical management consulting firm, released its 11th annual Dealmakers’ Intentions Study. The study indicates there will be an acceleration in dealmaking across all deal types and that buyers seem more willing to accept risk associated with opportunities in the early development and rare disease categories.
To view the study, visit here.